S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
New CBOE “special perk” helps traders target income every weekend (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
New CBOE “special perk” helps traders target income every weekend (Ad)
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
Economists predict US inflation will keep cooling and the economy can avoid a recession

Navidea Biopharmaceuticals Stock Price, News & Analysis (NYSE:NAVB)

$0.07
+0.02 (+40.08%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.05
$0.07
50-Day Range
$0.03
$0.10
52-Week Range
$0.02
$0.35
Volume
683,670 shs
Average Volume
338,672 shs
Market Capitalization
$7.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NAVB stock logo

About Navidea Biopharmaceuticals Stock (NYSE:NAVB)

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

NAVB Stock Price History

NAVB Stock News Headlines

Navidea Biopharmaceuticals, CRG Settle All Ongoing Litigation
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Navidea Biopharmaceuticals Inc NAVB
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
See More Headlines
Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Employees
11
Year Founded
N/A

Profitability

Net Income
$-15,180,000.00
Pretax Margin
-860,700.00%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
($0.03) per share

Miscellaneous

Free Float
56,367,000
Market Cap
$7.00 million
Optionable
Optionable
Beta
1.54
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Craig A. Dais CPA (Age 57)
    CFO & Principal Accounting Officer
  • Dr. Michael Sherman Blue F.A.C.E.P.
    M.D., Chief Medical Officer














NAVB Stock Analysis - Frequently Asked Questions

How have NAVB shares performed in 2023?

Navidea Biopharmaceuticals' stock was trading at $0.21 at the beginning of 2023. Since then, NAVB shares have decreased by 66.7% and is now trading at $0.0699.
View the best growth stocks for 2023 here
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced its earnings results on Tuesday, November, 14th. The company reported ($0.02) EPS for the quarter.

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:NAVB) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -